Results 41 to 50 of about 248,205 (145)

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2016
BACKGROUND Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).
J. Byrd, Bonnie K. Harrington, S. O'brien, Jeffrey A Jones, A. Schuh, S. Devereux, J. Chaves, W. Wierda, F. Awan, Jennifer R. Brown, P. Hillmen, D. Stephens, P. Ghia, J. Barrientos, J. Pagel, J. Woyach, D. Johnson, Jane Huang, Xiaolin Wang, A. Kaptein, B. Lannutti, T. Covey, M. Fardis, J. Mcgreivy, A. Hamdy, Wayne Rothbaum, R. Izumi, T. Diacovo, A. Johnson, R. Furman   +29 more
semanticscholar   +1 more source

Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes pro-survival stimuli to induce apoptosis in chronic lymphocytic leukemia cells [PDF]

, 2013
Purpose: Chronic lymphocytic leukemia (CLL) is currently incurable with standard chemotherapeutic agents, highlighting the need for novel therapies. Overcoming proliferative and cytoprotective signals generated within the microenvironment of lymphoid ...
Alison M. McCaig, Alison M. Michie, Byrd, Christian Berthou, Emilie Durieu, Emilio Cosimo, Helen Wheadon, Hervé Galons, Karine Le Ster, Kitada, Laurent Meijer, Luke J.M. Carter-Brzezinski, Michael T. Leach, Nassima Oumata, Pepper   +14 more
core   +1 more source

Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2019
BACKGROUND Data regarding the efficacy of treatment with ibrutinib-rituximab, as compared with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab, in patients with previously untreated chronic lymphocytic leukemia (CLL) have ...
T. Shanafelt, X. V. Wang, N. Kay, C. Hanson, S. O'brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K Singh, M. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman   +20 more
semanticscholar   +1 more source

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia

Leukemia, 2020
Characterizing antibody (Ab)-mediated immune response to SARS-CoV-2 is fundamental to understanding COVID-19 epidemiology, reinfection potential, and vaccine development, particularly in immunocompromised patients. The first report of SARS-CoV-2 directed
L. Roeker, D. Knorr, M. Pessin, L. Ramanathan, Meghan C. Thompson, L. Leslie, A. Zelenetz, A. Mato   +7 more
semanticscholar   +1 more source

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. [PDF]

, 2016
The clinical course of chronic lymphocytic leukaemia (CLL) is heterogeneous, and treatment options vary considerably. The Connect® CLL registry is a multicentre, prospective observational cohort study that provides a real-world perspective on the ...
Farber, Charles M, Flick, E Dawn, Flinn, Ian W, Flowers, Christopher R, Grinblatt, David L, Kay, Neil E, Kipps, Thomas J, Kiselev, Pavel, Kozloff, Mark F, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P, Sullivan, Kristen, Swern, Arlene S, Weiss, Mark A   +15 more
core   +1 more source

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations.

New England Journal of Medicine, 2020
Ibrutinib in CLL with TP53 Alterations Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations.
I. Ahn, X. Tian, A. Wiestner
semanticscholar   +1 more source

The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. [PDF]

, 2017
The study of long noncoding RNAs (lncRNAs) is an emerging area of cancer research, in part due to their ability to serve as disease biomarkers. However, few studies have investigated lncRNAs in chronic lymphocytic leukemia (CLL).
Blachly, James S, Chen, Timothy L, Coombes, Kevin R, Flinn, Ian W, Fobare, Sydney, Grever, Michael R, Hertlein, Erin K, Kipps, Thomas J, Lehman, Amy, Liu, Chaomei, Lucas, David M, Miller, Cecelia R, Rassenti, Laura Z, Ruppert, Amy S, Sampath, Deepa, Tallman, Martin S, Zhang, Xiaoli   +16 more
core   +1 more source

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment

American journal of hematology/oncology, 2019
Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course.
M. Hallek
semanticscholar   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

American journal of hematology/oncology, 2019
Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
T. Munir, Jennifer R. Brown, S. O'brien, J. Barrientos, P. Barr, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, T. Kipps, C. Moreno, M. Montillo, J. Burger, J. Byrd, P. Hillmen, S. Dai, A. Szoke, J. Dean, J. Woyach   +19 more
semanticscholar   +1 more source